FSD Pharma Announces Launch of IBS Clinical Study

beaker art

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy Read the full article…

Medical Marijuana NY-Based Biotech Company Enters Clinical Trials

Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies

NEW YORK:  AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus cannabidiol (CBD) gum at Wageningen University in the Netherlands. Human Clinical Trials Detail Include: Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the Read the full article…